ホーム / ニュース / サターラの発表、FDA が承認申請の審査用にサターラのバイオシミュレーションソフトウェアの使用を更新および拡張

サターラの発表、FDA が承認申請の審査用にサターラのバイオシミュレーションソフトウェアの使用を更新および拡張

FDA holds more than 400 SimcypTM and PhoenixTM software licenses across 12 divisions and offices

PRINCETON, N.J.— 2021 年 12 月 21 日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT)は、CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has renewed and expanded its licenses of Certara’s proprietary biosimulation software, with more than 400 user licenses of Simcyp and Phoenix software. In total, there are 12 divisions and offices of the FDA using Certara’s software for internal research and to independently analyze, verify and review regulatory submissions.

Certara’s Simcyp Simulator, an industry-leading platform for physiologically-based pharmacokinetic (PBPK) modeling and simulation, is used throughout the drug development process to evaluate new drug formulations, determine first-in-human dosing, optimize clinical study design and predict drug-drug interactions. The FDA has renewed its licenses for the Simcyp Simulator, Simcyp Paediatric and Simcyp Cardiac Safety Simulator, which the agency uses to independently analyze, verify and review investigational therapies, new drug applications and generic drug applications. 

“It is a privilege to continue providing software that global regulatory agencies can rely on to inform their reviews of regulatory submissions,” said William F. Feehery, Ph.D., CEO of Certara. “We are pleased that more scientists at the FDA are using our biosimulation software to support the development of safe and effective medicines.”

Additionally, the FDA has renewed and expanded its user licenses of Certara’s Phoenix Software, which is widely used for pharmacokinetic, pharmacodynamic and toxicokinetic modeling and simulation. Phoenix is used extensively to perform data analyses for new drug and biologics license applications by drug developers, including 37 of the top 40 global pharmaceutical companies by R&D spend.  The FDA uses Certara’s Phoenix software including WinNonlin, NLME and In Vitro-In Vivo Correlation (IVIVC) toolkit as well as the Company’s Trial Simulator software.

For more information on Certara’s software platforms, please visit https://www.certara.com/software/.


Certara(サターラ) について

サターラは、バイオシミュレーションソフトウェアと技術を用いて、従来の創薬・開発を変革し、医薬品をよりスピーディーに患者さんに届けることをミッションとしています。バイオ医薬品企業1,650社以上、主要学術機関、主要な規制当局がサターラのソフトウェアやコンサルティングサービスを利用しております。弊社のお客様は61か国以上に広がっております。

Certara Contact

Jieun W. Choe
jieun.choe@certara.com

メディア関係の皆様:

赤津笑美 emi.akatsu@certara.com
サターラ合同会社
daniel.yunger@kekstcnc.com
衣斐桃果
m-ebi@prap.co.jp
ariane.lovell@finnpartners.com

投資家の皆様:

David Deuchler
Gilmartin Groupir@certara.com

※英語または日本語でお問合せください

トップに戻る
Powered by Translations.com GlobalLink OneLink Software